Why Monte Rosa Therapeutics, Inc.’s (GLUE) Stock Is Up 6.86%
As of Tuesday, August 25, Monte Rosa Therapeutics, Inc.’s GLUE share price has surged by 6.86%, which has investors questioning if this is right time to sell.Michael Rose
Stock Evaluator: Monte Rosa Therapeutics, Inc. (GLUE)
Monte Rosa Therapeutics, Inc. GLUE
$13.84
-0.54
-3.76%
September 4, 2026 4:00:00 PM
EST
Volume: 804,576
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Biotechnology |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body’s natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1a, IL-1ß and IL-18, as well as damage-associated molecular patterns. In addition, it develops CDK2 to treat multiple cancers, including ovarian, endometrial, gastric and breast. Further, its pipeline includes programs in immunology and inflammation indications, oncology, cardiovascular, metabolic, and genetic diseases. The company also develops QuEEN, a discovery engine, to enable its target-centric MGD discovery and development approach and its rational design of MGD product candidates. It has a strategic collaboration and licensing agreement with F. Hoffmann-La Roche Ltd.; and Novartis. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.
Commentary & Analysis
Why Monte Rosa Therapeutics, Inc.’s (GLUE) Stock Is Down 5.73%
As of Monday, August 24, Monte Rosa Therapeutics, Inc.’s GLUE share price has dipped by 5.73%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Monte Rosa Therapeutics, Inc.’s (GLUE) Stock Is Up 6.70%
As of Friday, August 21, Monte Rosa Therapeutics, Inc.’s GLUE share price has surged by 6.70%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Monte Rosa Therapeutics, Inc.’s (GLUE) Stock Is Up 5.56%
As of Wednesday, August 19, Monte Rosa Therapeutics, Inc.’s GLUE share price has surged by 5.56%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Is Monte Rosa Therapeutics, Inc. (GLUE) Overvalued?
We dive into why Monte Rosa Therapeutics, Inc. (GLUE) could be considered overvalued on 2026-08-07, based on AAII’s Value Score and Grade.Tudor Pop
Financial Summary
| Share Statistics | GLUE | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,180.7 | $282.4 | 47% |
|
| Shares Out (Mil) | 101.5 | 54.0 | 62% |
|
| Institutional Ownership | 99.3% | 93.1% | 86% |
|
| Float (Mil) | 54.5 | 42.2 | 49% |
|
| Beta | 1.53 | 0.94 | 83% |
|
| Avg Daily Volume (000s) | 1,097 | 482 | 74% |
|
| Price Change (52-week) |
181.9% | 59.9% | 97% |
|
| Growth | GLUE | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 14.1% | na |
|
| Net Income (5yr) | (1.5%) | (10.1%) | 38% |
|
| EPS (5yr) | 54.4% | 15.9% | 94 |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | (15.4%) | (15.6%) | 49% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 7 | 7 | 7 | |
| Current EPS | ($0.347) | ($1.566) | ($1.876) | |
| Month Ago EPS | ($0.380) | ($1.599) | ($1.814) | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | ($0.380) | ($1.592) | ($1.815) | |
| Year/Year Chg | (19.3%) | 236.8% | 252.5% | |
| Financials | GLUE | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $29 | $37 | 15% |
|
| Net Income (TTM) (Mil) | ($161) | ($43) | 8% |
|
| EPS (TTM) | ($1.745) | ($1.500) | 16% |
|
| Operating Cash Flow (TTM) (Mil) | ($24) | ($31) | 14% |
|
| Net Cash Flow (TTM) (Mil) | $21 | $2 | 62% |
|
| Long-Term Debt (Q1) (Mil) | $33 | $4 | 36% |
|
| Enterprise Value (Q1) (Mil) | $772 | $190 | 38% |
|
| Valuation | GLUE | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.42 | 2.84 | 57% |
|
| P/E | na | 20.2 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | GLUE | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (465.2%) | 66.9% | 0% |
|
| Net Margin | (560.9%) | (74.2%) | 1% |
|
| ROA | (30.7%) | (47.7%) | 17% |
|
| ROE | (42.7%) | (55.0%) | 17% |
|
| Liabilities to Assets | 29.5% | 29.8% | 21% |
|
| F-Score | 3 | 3 | 18% |
|
Monte Rosa Therapeutics, Inc. did not pass any screens on 9/4/2026.
